CA
COGT icon

Cliff Asness’s Cogent Biosciences COGT Stock Holding History

Cliff Asness’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4M Buy
294,913
+105,117
+55% +$3.68M ﹤0.01% 1486
2026
Q1 		$7.31M Buy
189,796
+67,996
+56% +$2.51M ﹤0.01% 1510
2025
Q4 		$4.33M Buy
121,800
+4,959
+4% +$139K ﹤0.01% 1659
2025
Q3 		$1.68M Buy
116,841
+71,760
+159% +$850K ﹤0.01% 2095
2025
Q2 		$324K Sell
45,081
-115,686
-72% -$641K ﹤0.01% 2834
2025
Q1 		$963K Buy
160,767
+133,174
+483% +$1.04M ﹤0.01% 2035
2024
Q4 		$215K Buy
27,593
+15,881
+136% +$158K ﹤0.01% 2646
2024
Q3 		$126K Buy
+11,712
New +$114K ﹤0.01% 2633
2023
Q3 		– Sell
-13,633
Closed -$161K – 2326
2023
Q2 		$161K Sell
13,633
-2,688
-16% -$30.8K ﹤0.01% 2105
2023
Q1 		$176K Sell
16,321
-7,228
-31% -$92.5K ﹤0.01% 2068
2022
Q4 		$272K Buy
+23,549
New +$292K ﹤0.01% 2003

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cliff Asness's COGT Position: Q2 2026 in Review

Cliff Asness increased its Cogent Biosciences (COGT) stake by 55% in Q2 2026, buying an estimated $3.68M and bringing the position to 294,913 shares worth $11.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1486.

Cliff Asness first reported a position in COGT in Q4 2022 and has held it in 11 quarters since. 321 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Cliff Asness held 294,913 shares of Cogent Biosciences worth $11.4M as of Q2 2026.
  • Cliff Asness bought 105,117 Cogent Biosciences shares in Q2 2026, an estimated $3.68M.
  • Cogent Biosciences made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #1486 holding.
  • Cliff Asness first reported a position in Cogent Biosciences in Q4 2022 and has held it in 11 quarters since.
  • 321 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.